Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
Executive Reshuffles: NIO, Pfizer and Spirit Airlines in Focus
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Novo Nordisk A/S (NYSE:NVO), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.'s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees an
Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code
Novo Nordisk (NVO) was publicly reprimanded Friday by industry regulators in the UK for not disclosing payments amounting to roughly 7.8 million pounds ($10 million) within a three-year period. The Pr
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches
The Association of the British Pharmaceutical Industry's Prescription Medicines Code of Practice Authority flagged four major pharmaceutical companies for breaching its regulations. The British trade
'FDA to Evaluate Potential Risk of Neural Tube Birth Defects With HIV Medicine Dolutegravir (Juluca, Tivicay, Triumeq)' - FDA
'FDA to Evaluate Potential Risk of Neural Tube Birth Defects With HIV Medicine Dolutegravir (Juluca, Tivicay, Triumeq)' - FDA
Pfizer Names Former State Street CEO Taraporevala to Board
Pfizer Inc. (NYSE:PFE) Is Favoured by Institutional Owners Who Hold 68% of the Company
Si Usted Compró, Pagó O Proporcionó Un Reembolso Por Una Parte O La Totalidad Del Precio De Lipitor De Marca O Su Equivalente Genérico, Atorvastatina Cálcica, Usted Podría Obtener Dinero De Una Conciliación
TRENTON, N.J., 3 de julio de 2024 /PRNewswire-HISPANIC PR WIRE/ -- SUS DERECHOS LEGALES PUEDEN VERSE AFECTADOS Existe una conciliación propuesta en una demanda colectiva presentada contra Pfizer Inc
What the Options Market Tells Us About Pfizer
Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 8 unusual trades.Delving into the details, we found 37% of traders were
GSK Will Pay Up to $1.5 Billion for CureVac's MRNA Vaccines -- Barrons.com
By Josh Nathan-Kazis The drugmaker GSK plunged into the messenger RNA-based vaccine market Wednesday, announcing it will buy the rights to experimental influenza and Covid-19 mRNA vaccines from the b
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Wednesday, GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) announced they have restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investme
Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
(Updates with statement from GSK in fourth and fifth paragraphs.) A Delaware Superior Court judge rejected an appeal from GSK (GSK) and other drugmakers to overturn a ruling that cleared the way for o
After falling to an 11-year low and consolidating for several months, should I buy or sell pfizer (PFE.US) now?
In April of this year, Pfizer (PFE.US) stock price fell to its lowest point since January 2013. As of the closing price on July 1, the stock has risen by about 11% since then; After falling to an 11-year low, Pfizer has been consolidating for several months. So, should you buy or sell Pfizer stocks now? From a fundamental perspective, Pfizer is still trying to overcome the drag from the cooling of its COVID-19 products and actively promote the development of non-COVID-19 drug business. Recently, the company announced positive trial results of two potential anticancer drugs, but also closed a gene therapy project, and the company's stock price continues to trade sideways. In a study, patients who received Pfizer Elrex
Pfizer Options Spot-On: On July 2nd, 90,664 Contracts Were Traded, With 2.74 Million Open Interest
On July 2nd ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 90,664 options for the day, of which put options accounted for 49.39% of the total transactions, and call op
Atopic Dermatitis Market to Register Incremental Growth by 2034, Examines DelveInsight | Key Companies - Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant Sciences, Cara Therapeutics, Pfizer, Arena Pharmaceuticals
New York, USA, July 02, 2024 (GLOBE NEWSWIRE) -- Atopic Dermatitis Market to Register Incremental Growth by 2034, Examines DelveInsight | Key Companies - Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant
COVID Infections Could Be Seeing a Summer Surge Based on CDC Data
Unusual Options Activity: CRH, CPNG and Others Attract Market Bets, CRH V/OI Ratio Reaches 312.5
EST Jul 2nd Morning Delivery - In the last two hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.Of
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case
Moderna (0QF.F) and its rivals Pfizer (PFE.F) and BioNTech (22UA.F) are considering appeals after London's High Court handed down a mixed ruling in their patent dispute relating to the mRNA technology